Rocket Pharmaceuticals, Inc. (RCKT)
Automate Your Wheel Strategy on RCKT
With Tiblio's Option Bot, you can configure your own wheel strategy including RCKT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RCKT
- Rev/Share 0.0
- Book/Share 3.7435
- PB 0.756
- Debt/Equity 0.0615
- CurrentRatio 9.1896
- ROIC -0.616
- MktCap 304898540.0
- FreeCF/Share -1.9336
- PFCF -1.4323
- PE -1.2075
- Debt/Assets 0.0538
- DivYield 0
- ROE -0.6492
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | RCKT | Evercore ISI | Outperform | In-line | -- | $5 | May 30, 2025 |
| Downgrade | RCKT | Leerink Partners | Outperform | Market Perform | -- | $8 | May 28, 2025 |
| Downgrade | RCKT | Jefferies | Buy | Hold | -- | $2.5 | May 28, 2025 |
| Downgrade | RCKT | Morgan Stanley | Overweight | Equal Weight | -- | $7 | May 28, 2025 |
| Downgrade | RCKT | Goldman | Neutral | Sell | -- | $2 | May 28, 2025 |
| Downgrade | RCKT | JP Morgan | Overweight | Neutral | -- | -- | May 28, 2025 |
| Downgrade | RCKT | Needham | Buy | Hold | -- | -- | May 27, 2025 |
| Downgrade | RCKT | TD Cowen | Buy | Hold | -- | -- | May 27, 2025 |
| Initiation | RCKT | BMO Capital Markets | -- | Outperform | -- | $50 | March 12, 2025 |
| Initiation | RCKT | Wedbush | -- | Outperform | -- | $32 | Dec. 30, 2024 |
News
Rocket Pharmaceuticals shares plunge after FDA halts key gene therapy trial following patient death
Published: May 27, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) sank nearly 60% on Tuesday morning after the company disclosed that the US Food and Drug Administration had placed a clinical hold on its pivotal Phase II trial for Danon disease, a rare genetic heart disorder, following the death of a patient in the study. The patient experienced a serious adverse event (SAE) of capillary leak syndrome and subsequently died due to an acute systemic infection, according to reports.
Read More
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
Read More
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
Read More
Rocket Pharma Is A Buy At These Prices With Promising Data
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Positive
Rocket Pharmaceuticals, Inc.'s RP-L201 for LAD-I faces FDA rejection but shows promising data; potential approval could unlock a $350M market. RP-L102 for Fanconi Anemia and RP-A501 for Danon Disease show strong clinical data, indicating significant market potential. Financially, Rocket Pharma has a limited cash runway of 2–4 quarters, dependent on FDA approvals and successful public offerings.
Read More
About Rocket Pharmaceuticals, Inc. (RCKT)
- IPO Date 2015-02-18
- Website https://rocketpharma.com
- Industry Biotechnology
- CEO Dr. Gaurav D. Shah M.D.
- Employees 299